Stock Track | Zymeworks (ZYME) Soars 5.06% as Leerink Partners Reiterates Buy Rating with $30 Price Target

Stock Track

Aug 13, 2025

Zymeworks Inc. (ZYME) stock is experiencing a significant uptick in Tuesday's trading session, soaring 5.06% following a bullish analyst report. The surge comes as investors react positively to the reiterated confidence in the healthcare company's prospects.

In a report released today, Andrew Berens from Leerink Partners maintained a Buy rating on Zymeworks, coupled with an ambitious price target of $30.00. This price target suggests substantial upside potential from the stock's current trading levels, igniting investor enthusiasm and driving the stock's impressive intraday performance.

The reaffirmed positive stance from a respected financial services firm like Leerink Partners appears to have bolstered investor confidence in Zymeworks' future. As the healthcare sector continues to attract attention, ZYME's strong movement today underscores the market's favorable reaction to positive analyst sentiment, particularly in growth-oriented biotech stocks.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1178974196"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178974196\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178974196?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-13 03:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178974196","market":"us","top_or_hot":-1,"title":"Stock Track | Zymeworks (ZYME) Soars 5.06% as Leerink Partners Reiterates Buy Rating with $30 Price Target","media":"Stock Track","content":"<p>Zymeworks Inc. (ZYME) stock is experiencing a significant uptick in Tuesday's trading session, soaring 5.06% following a bullish analyst report. The surge comes as investors react positively to the reiterated confidence in the healthcare company's prospects.</p>\n\n<p>In a report released today, Andrew Berens from Leerink Partners maintained a Buy rating on Zymeworks, coupled with an ambitious price target of $30.00. This price target suggests substantial upside potential from the stock's current trading levels, igniting investor enthusiasm and driving the stock's impressive intraday performance.</p>\n\n<p>The reaffirmed positive stance from a respected financial services firm like Leerink Partners appears to have bolstered investor confidence in Zymeworks' future. As the healthcare sector continues to attract attention, ZYME's strong movement today underscores the market's favorable reaction to positive analyst sentiment, particularly in growth-oriented biotech stocks.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Zymeworks (ZYME) Soars 5.06% as Leerink Partners Reiterates Buy Rating with $30 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Zymeworks (ZYME) Soars 5.06% as Leerink Partners Reiterates Buy Rating with $30 Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-13 03:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zymeworks Inc. (ZYME) stock is experiencing a significant uptick in Tuesday's trading session, soaring 5.06% following a bullish analyst report. The surge comes as investors react positively to the reiterated confidence in the healthcare company's prospects.</p>\n\n<p>In a report released today, Andrew Berens from Leerink Partners maintained a Buy rating on Zymeworks, coupled with an ambitious price target of $30.00. This price target suggests substantial upside potential from the stock's current trading levels, igniting investor enthusiasm and driving the stock's impressive intraday performance.</p>\n\n<p>The reaffirmed positive stance from a respected financial services firm like Leerink Partners appears to have bolstered investor confidence in Zymeworks' future. As the healthcare sector continues to attract attention, ZYME's strong movement today underscores the market's favorable reaction to positive analyst sentiment, particularly in growth-oriented biotech stocks.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZYME","symbol_name":"ZYMEWORKS INC (US)","start_time":0,"source_url":"","article_id":"1178974196","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178974196","pubTimestamp":1755027627,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Zymeworks Inc. (ZYME) stock is experiencing a significant uptick in Tuesday's trading session, soaring 5.06% following a bullish analyst report. The surge comes as investors react positively to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZYME":"ZYMEWORKS INC (US)"},"translate_title":"股票追踪|Leerink Partners重申买入评级，目标价30美元，Zymeworks(ZYME)飙升5.06%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZYME":1},"content_text":"Zymeworks Inc. (ZYME) stock is experiencing a significant uptick in Tuesday's trading session, soaring 5.06% following a bullish analyst report. The surge comes as investors react positively to the reiterated confidence in the healthcare company's prospects.\nIn a report released today, Andrew Berens from Leerink Partners maintained a Buy rating on Zymeworks, coupled with an ambitious price target of $30.00. This price target suggests substantial upside potential from the stock's current trading levels, igniting investor enthusiasm and driving the stock's impressive intraday performance.\nThe reaffirmed positive stance from a respected financial services firm like Leerink Partners appears to have bolstered investor confidence in Zymeworks' future. As the healthcare sector continues to attract attention, ZYME's strong movement today underscores the market's favorable reaction to positive analyst sentiment, particularly in growth-oriented biotech stocks.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}